Dicerna Pharmaceuticals, Inc.

Company Summary

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases.

Transaction Overview

July 30, 2013: Dicerna Pharmaceuticals, Inc. announced a private placement of 8,142,891 shares of Series C preferred stock at a price of $7 per share to (18) accredited investors for gross proceeds of $57,000,237.
The investment was led by RA Capital Management, LLC., and included participation from Bain Public Capital, LLC, Deerfield Capital Management, LLC, and Omega Fund Management UK LLP, and existing investors Abingworth LLP, Domain Associates, L.L.C., Oxford Bioscience Partners, Skyline Ventures, and SR One.

‍

Significance of the Transaction

The Series C financing permits the Company to expand its specialty contract manufacturing capabilities and broaden existing strategic partnerships with global generics manufacturers

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

PRE-IPO/IPO

Dicerna Pharmaceuticals, Inc.

Has completed a $60,000,000 series C financing led by

The undersigned acted as an exclusive advisor to Dicerna